DOCSLIB.ORG

Evaluation of Dyskinesias in a Pilot, Randomized, Placebo-Controlled Trial of Remacemide in Advanced Parkinson Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evaluation of Dyskinesias in a Pilot, Randomized, Placebo-Controlled Trial of Remacemide in Advanced Parkinson Disease ORIGINAL CONTRIBUTION Evaluation of Dyskinesias in a Pilot, Randomized, Placebo-Controlled Trial of Remacemide in Advanced Parkinson Disease Parkinson Study Group Context: Long-term levodopa therapy for Parkinson dis- (MGDRS), a newly created Lang-Fahn Activities of Daily ease commonly results in motor complications includ- Living Dyskinesia scale (LFADLDS), and diary dyskine- ing “on-off” fluctuations and dyskinesias, but it is still sia ratings. unclear how best to assess treatment effects on dyskine- sias in clinical trials. Results: Patient and investigator diaries showed excel- lent agreement in dyskinesia ratings. The MGDRS score Objective: To compare several methods of rating le- correlated with clinic diary ratings of the percentage of vodopa-induced dyskinesias to evaluate the effect of rema- “on” time with dyskinesias, and the LFADLDS score cor- cemide hydrochloride treatment in patients with ad- related with home and clinic diary assessments of per- vanced Parkinson disease. centage of on time with severe dyskinesias. The MGDRS score did not correlate highly with the LFADLDS score. Design: Two-week multicenter randomized, double- This pilot study also validated previous results demon- blind, placebo-controlled, parallel-group study. strating the safety and tolerability of remacemide treat- ment for advanced Parkinson disease but did not result Setting: Five academic sites of the Parkinson Study Group. in any demonstrable improvement or worsening in dys- kinesia measures. Patients: Thirty-nine subjects at least 30 years old with idiopathic Parkinson disease and disabling dyskinesias. Conclusions: Diaries may provide a valid means of evalu- ating dyskinesias in clinical trials for Parkinson disease, Interventions: Randomly received daily doses of 150 but there remain other aspects of dyskinesias, as as- mg, 300 mg, or 600 mg of remacemide hydrochloride or sessed by the MGDRS and LFADLDS, that are not re- matching placebo for 2 weeks. flected in diary ratings. Main Outcome Measures: The dyskinesia rating scales used were the Modified Goetz Dyskinesia Rating scale Arch Neurol. 2001;58:1660-1668 ITHIN 5 years of di- sonian response in both primates and ro- agnosis approxi- dents.6,9,10 Oh and colleagues11 have mately half of the reported that intermittent stimulation of patients with Par- normally functioning dopaminergic re- kinson disease (PD) ceptors activates intraneuronal signaling Wtreated with levodopa develop motor com- pathways in striatal spiny neurons that al- plications, including “on-off” fluctuations ters the phosphorylation state of coex- and dyskinesias.1 Dyskinesias often ex- pressed NMDA glutamate receptors. This hibit a dose-dependent relationship with causes an increased sensitivity of these glu- dopaminergic therapy, diminishing with tamatergic receptors to cortical input to the dosage decreases and worsening with in- striatum and consequent motor fluctua- creases.2 The pathophysiological origins of tions and dyskinesias.11,12 Thus, NMDA an- these phenomena have not been defini- tagonists may reduce or prevent the de- tively established; however, the mecha- velopment of these motor complications. nism underlying the development of dys- Remacemide hydrochloride is a non- kinesias may be distinct from that of competitive NMDA channel antagonist levodopa’s antiparkinsonian properties.3-8 with antiparkinsonian efficacy in rodent Systemic administration of N- and primate models of PD when used in methyl D-aspartate (NMDA) antagonists combination with levodopa, but not when A complete list of the authors can ameliorate levodopa-induced dyski- administered alone.13 It is safe and well tol- appears on page 1668. nesias without a reduction in antiparkin- erated in patients with PD, and prelimi- ARCH NEUROL / VOL 58, OCT 2001 WWW.ARCHNEUROL.COM 1660 ©2001 American Medical Association. All rights reserved. (REPRINTED WITH CORRECTIONS) Downloaded From: https://jamanetwork.com/ on 09/23/2021 PATIENTS AND METHODS these diaries by each patient, extensive instructions were given, an instructional videotape classifying dyskinesia severity was shown, and a training and practice scoring session was done PATIENTS with the investigator. During this session, the patient had to beseeninboth “fulloff”and“onwithseveredyskinesias”states Thirty-nine patients with idiopathic PD were enrolled from (adjusting the dosage and timing of antiparkinsonian medi- 5 sites of the Parkinson Study Group (Figure 2). Sub- cations, if necessary, to do so), and complete agreement be- jects were aged 30 years or older and had disabling dyski- tween the patient and the investigator on the classification of nesias that were defined by their presence historically greater all observed clinical states had to be achieved. Patients were than 25% of the average waking day (ie, score Ն2onthe then given home dyskinesia diaries to fill out on each of 3 con- Unified Parkinson’s Disease Rating Scale [UPDRS], part IV secutive days immediately prior to the baseline visit. [complications of therapy], item 32 [What proportion of Within 14 days, qualified patients returned for base- the waking day are dyskinesias present?]) and interfer- line evaluation and the 3-day home diaries were reviewed. ence with activities of daily living to at least a moderate ex- At this time, pretreatment clinical assessments were also tent (ie, score Ն2 on the UPDRS, part IV, item 33 [How performed during an observation period of 6 hours. Pa- disabling are the dyskinesias?], and a score of 2 or more tients were instructed to take their usual doses of antipar- on at least 2 of the 5 items in the LFADLDS [Table 1]). Sub- kinsonian medications with a low-protein breakfast prior jects were treated with stable optimized dosages of le- to arrival at the clinic and to report to the research center vodopa for at least 2 to 4 weeks prior to enrollment, and for the study visit at a fixed time (9 AM). All antiparkinso- could be taking stable dosages of selegiline hydrochlo- nian medications were given on a predefined schedule iden- ride, dopamine agonists, or catechol O-methyltransferase tical to the patient’s schedule at home, and a standardized inhibitors. Patients were excluded if they were taking medi- lunch was provided at a set hour. cations that could potentially alter parkinsonism, affect dys- At the end of the baseline visit, subjects were ran- kinesias, or interfere with the metabolism or mechanism domly assigned to receive remacemide hydrochloride, 150 of action of the study medication, or if there was evidence mg/d, 300 mg/d, or 600 mg/d, or matching placebo, in 2 of significant depression, dementia, psychosis, or other se- divided doses 12 hours (±2 hours) apart. The computer- rious medical conditions. generated randomization plan included stratification by cen- ter and blocking to ensure approximate balance among the PROCEDURES treatment groups within each center. Sites telephoned the Parkinson Study Group Coordination Center, Rochester, After informed consent was obtained, screening medical NY, to enroll patients, and patient identification numbers and laboratory evaluations were performed with the were assigned through an interactive computer module. Pa- patient in the “on” state (ie, with good function). Clinical tients were then instructed to fill out another set of 3 home assessments included the modified Hoehn and Yahr scale, diaries immediately prior to the next visit. UPDRS parts I to IV (ie, mentation, activities of daily liv- Administration of medication was initiated on the ing [ADL], motor function, and complications of therapy, evening of the baseline visit and titrated up to the as- respectively), Clinical Global Impressions scale, Schwab signed dosage over 5 days. This intervention continued for and England ADL scale, Mini-Mental State Examination, a total of 2 weeks. If a patient developed intolerance to the and the Beck Depression Inventory. Measures of dyskine- medication, a change from the twice daily regimen to a 4 sia severity were also obtained (described in the “Dyski- times daily regimen, without changing the total daily dos- nesia Outcome Measures” subsection of the “Patients and age, was recommended. Methods” section), and the home dyskinesia diaries were introduced. To ensure reliable and accurate completion of Continued on next page nary studies indicate that it may improve motor fluctua- (LFADLDS) (Table 1), and dyskinesia diary rating cards tions in levodopa-treated patients.14,15 Whether it has a (Figure 1). significant effect on dyskinesias has not yet been estab- lished, but it has been suggested that an NMDA antago- RESULTS nist effect accounts for the efficacy of amantadine hy- drochloride treatment in improving levodopa-induced SUBJECT CHARACTERISTICS dyskinesias.16 We planned this preliminary multicenter random- Baseline characteristics of the 4 treatment groups are given ized, double-blind, placebo-controlled, parallel-group in Table 2. Overall, patients’ ages averaged (±SD) study to evaluate the effects of 3 different dosages of rema- 64.3±8.4 years and they had a diagnosis of PD for cemide in patients with PD who have disabling dyski- 13.3±5.8 years (mean±SD). Patients spent 75.4%±16.1% nesias. Since no standard criterion for the evaluation of (mean±SD) of the waking day in the on state on aver- dyskinesia severity within a clinical trial exists and the age, including 59.5%±19.9% (mean±SD) of the waking problem is multifaceted, we used several methods of as- day with dyskinesias and 28.5%±25.7% (mean±SD) with sessment to determine
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green Et Al
    US009381189B2 (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green et al. (45) Date of Patent: Jul. 5, 2016 (54) INGREDIENTS FOR INHALATION AND (56) References Cited METHODS FOR MAKING THE SAME U.S. PATENT DOCUMENTS (75) Inventors: Matthew Michael James Green, 4,582,265 A * 4/1986 Petronelli ....................... 241.95 Wiltshire (GB); Richard Michael Poole, 6,257,233 B1 7/2001 Burr et al. 2004/01 18007 A1* 6/2004 Chickering et al. ............ 34/360 Wiltshire (GB) 2006, O257491 A1* 11, 2006 Morton et al. ... 424/489 (73) Assignee: VECTURA LIMITED, Wiltshire (GB) 2008/0063719 A1 3/2008 Morton et al. ................ 424/489 (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 EP O709086 A2 5, 1996 U.S.C. 154(b) by 641 days. EP 14981 16 A1 1, 2005 GB 2387781 A 10, 2003 JP 2005298.347 10/2005 (21) Appl. No.: 13/514,672 JP 200954.1393 11, 2009 JP 2012,542618 6, 2012 (22) PCT Fled: Dec. 8, 2010 WO 96.23485 A1 8, 1996 WO 9703649 A1 2, 1997 (86) PCT NO.: PCT/GB2O10/052053 WO O2OO197 A1 1, 2002 WO O243701 A2 6, 2002 S371 (c)(1), WO 2005105043 A2 11/2005 Aug. 20, 2012 WO 2007053904 A1 5/2007 (2), (4) Date: WO 2008.000482 1, 2008 (87) PCT Pub. No.: WO2O11AO70361 WO 2009095684 A1 8, 2009 OTHER PUBLICATIONS PCT Pub. Date: Jun. 16, 2011 Brunauer et al. "Adsorption of Gases in Multimolecular Layers'. J. (65) Prior Publication Data Am.
    [Show full text]
  • Nomination Background: Ketamine Hydrochloride (CASRN: 1867-66-9)
    KETAMINE Nomination TABLE OF CONTENTS Page 1.0 BASIS OF NOMINATION 1 2.0 BACKGROUND INFORMATION 1 3.0 CHEMICAL PROPERTIES 2 3.1 Chemical Identification 2 3.2 Physico-Chemical Properties 3 3.3 Purity and Commercial Availability 4 4.0 PRODUCTION PROCESSES AND ANALYSIS 6 5.0 PRODUCTION AND IMPORT VOLUMES 7 6.0 USES 7 7.0 ENVIRONMENTAL OCCURRENCE 7 8.0 HUMAN EXPOSURE 7 9.0 REGULATORY STATUS 7 10.0 CLINICAL PHARMACOLOGY 7 11.0 TOXICOLOGICAL DATA 13 11.1 General Toxicology 13 11.2 Neurotoxicology 14 12.0 CONCLUSIONS 15 APPENDIX A 17 APPENDIX B 23 APPENDIX C 27 1 KETAMINE 1.0 BASIS OF NOMINATION Ketamine, a noncompetitive NMDA receptor blocker, has been used extensively off - label as a pediatric anesthetic for surgical procedures in infants and toddlers. Recently, Olney and coworkers have demonstrated severe widespread apoptotic degeneration throughout the rapidly developing brain of the 7-day-old rat after ketamine administration. Recent research at FDA has confirmed and extended Olney’s observations. These findings are cause for concern with respect to ketamine use in children. The issue of whether the neurotoxicity found in this animal model (rat) has scientific and regulatory relevance for the pediatric use of ketamine relies heavily upon confirmation of these findings that may be obtained from the conduct of an appropriate study in non-human primates. 2.0 BACKGROUND INFORMATION The issue of potential ketamine neurotoxicity in children surfaced as a result of FDA’s reluctance to approve an NIH pediatric clinical trial using this compound because of its documented neurotoxic effects in young rats (published in several papers over the last ten years by Olney and co-workers).
    [Show full text]
  • The Effects of Ketamine on Dopaminergic Function
    THE EFFECTS OF KETAMINE ON DOPAMINERGIC FUNCTION Michelle Kokkinou Psychiatric Imaging Group London Institute of Medical Sciences (LMS), Medical Research Council (MRC) Faculty of Medicine, Imperial College London Thesis submitted for the degree of Doctor of Philosophy 1 Declaration of originality The experiments described and data analysis were part of my own work, unless otherwise stated. The work was conducted at the London Institute of Medical Sciences (LMS) in collaboration with Imanova Ltd. Specialist pre-clinical imaging analysis was conducted in collaboration with Mattia Veronese (King’s College London). Specialist meta-analysis was conducted in collaboration with Abhishekh Ashok. Peer-reviewed accepted paper Michelle Kokkinou, Abhishekh H Ashok, Oliver D Howes. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Molecular Psychiatry. Oct 3. doi: 10.1038/mp.2017.190. Published conference abstracts arising from this thesis Chapters 3&4: Howes OD., Kokkinou M. The Effects of Repeated NMDA Blockade with Ketamine on Dopamine and Glutamate Function. Biological Psychiatry. 72nd Annual Scientific Convention and Meeting. https://doi.org/10.1016/j.biopsych.2017.02.091 Chapters 4&5: Kokkinou M, Irvine EE, Bonsall DR Ungless MA, Withers DJ, Howes OD. Modulation of sub-chronic ketamine-induced locomotor sensitisation by midbrain dopamine neuron firing. European Neuropsychopharmacology (ENP) Chapters 3 & 4 are in preparation for publication. Presentation regarding the experiments in this thesis British Association for Psychopharmacology Meeting July 2017. Midbrain dopamine neuron firing mediates the effects of ketamine treatment on locomotor activity: A DREADD experiment 2 Copyright Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives Licence.
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • Driver Impairment, Accident Risk and Tolerance
    IMMORTAL D-R4.4 21/10/04 Deliverable D-R4.4 EXPERIMENTAL STUDIES ON THE EFFECTS OF LICIT AND ILLICIT DRUGS ON DRIVING PERFORMANCE, PSYCHOMOTOR SKILLS AND COGNITIVE FUNCTION Public IMMORTAL CONTRACT NO GMAI-2000-27043 SI2.319837 Project Co-ordinator: Prof. Bob Hockey, University of Leeds Workpackage Leader: Inger Marie Bernhoft, Danish Transport Research Institute Authors: JG Ramaekers, KPC Kuypers, Brain & Behavior Institute, Faculty of Psychology, Maastricht University CM Wood, GRJ Hockey, S Jamson, H Jamson, E Birch, School of Psychology, University of Leeds Date: 28.09.2004 Project Funded by the European Commission under the Transport RTD Programme of the 5th Framework Programme i IMMORTAL D-R4.4 21/10/04 School of Psychology, UNIV LEEDS DOCUMENT CONTROL INFORMATION Title Experimental studies on the effects of licit and illicit drugs on driving performance, psychomotor skills and cognition Author(s) JG Ramaekers, KPC Kuypers, CM Wood, GRJ Hockey, S Jamson, H Jamson, E Birch Editor(s) Date 28/09/2004 Report Number Reference and version Version 1 number Distribution Project Consortium Availability Public File QA check Nic Ward Authorised by Bob Hockey Signature ii IMMORTAL D-R4.4 21/10/04 Table of Contents 1. INTRODUCTION.............................................................................................................10 1.1 GENERAL BACKGROUND....................................................................................10 1.2 TASK DESCRIPTION.............................................................................................11
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Understanding History, and Not Repeating It. Neuroprotection For
    Clinical Neurology and Neurosurgery 129 (2015) 1–9 Contents lists available at ScienceDirect Clinical Neurology and Neurosurgery jo urnal homepage: www.elsevier.com/locate/clineuro Review Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview a a b b,c a,b,c,d,∗ Stephen Grupke , Jason Hall , Michael Dobbs , Gregory J. Bix , Justin F. Fraser a Department of Neurosurgery, University of Kentucky, Lexington, USA b Department of Neurology, University of Kentucky, Lexington, USA c Department of Anatomy and Neurobiology, University of Kentucky, Lexington, USA d Department of Radiology, University of Kentucky, Lexington, USA a r t i c l e i n f o a b s t r a c t Article history: Background: Neuroprotection for ischemic stroke is a growing field, built upon the elucidation of the Received 17 April 2014 biochemical pathways of ischemia first studied in the 1970s. Beginning in the early 1990s, means by Received in revised form 7 November 2014 which to pharmacologically intervene and counteract these pathways have been sought, though with Accepted 13 November 2014 little clinical success. Through a comprehensive review of translations from laboratory to clinic, we aim Available online 3 December 2014 to evaluate individual mechanisms of action, while highlighting potential barriers to success that will guide future research. Keywords: Methods: The MEDLINE database and The Internet Stroke Center clinical trials registry were queried Acute stroke Angiography for trials involving the use of neuroprotective agents in acute ischemic stroke in human subjects. For the purpose of the review, neuroprotective agents refer to medications used to preserve or protect the Brain ischemia Drug trials potentially ischemic tissue after an acute stroke, excluding treatments designed to re-establish perfusion.
    [Show full text]
  • Juvenile Onset Huntington's Disease • Peggy C
    Juvenile Onset Huntington's Disease Onset Huntington's Juvenile • Peggy • C. Nopoulos Juvenile Onset Huntington's Disease Edited by Peggy C. Nopoulos Printed Edition of the Special Issue Published in Brain Sciences www.mdpi.com/journal/brainsci Juvenile Onset Huntington’s Disease Juvenile Onset Huntington’s Disease Editor Peggy C. Nopoulos MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Editor Peggy C. Nopoulos University of Iowa USA Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Actuators (ISSN 2076-0825) (available at: https://www.mdpi.com/journal/brainsci/special issues/ Juvenile Huntington Disease). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Volume Number, Page Range. ISBN 978-3-03943-811-2 (Hbk) ISBN 978-3-03943-812-9 (PDF) c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Editor .............................................. vii Preface to ”Juvenile Onset Huntington’s Disease” .......................... ix Peg C. Nopoulos Special Issue: Juvenile Onset Huntington’s Disease Reprinted from: Brain Sci.
    [Show full text]
  • Huntington's Disease: Progress and Potential in the Field
    Review 1 Central & Peripheral Nervous Systems Huntington’s disease: progress 5 and potential in the fi eld † Edward C Stack & Robert J Ferrante 1. Background † Boston University School of Medicine , Departments of Neurology , Pathology, and Psychiatry, 2. Existing clinical Edith Nourse Rogers Veterans Administration Medical Center , Experimental Neuropathology Unit 10 management and need and Translational Therapeutics Laboratory , GRECC Unit, Building 18 , 3. Mechanisms of cell death and Bedford, MA 01730 , USA potential therapeutic targets in Huntington’s disease While the first description of Huntington’s disease was reported over a century ago, no therapy exists that can halt or ameliorate the inexorable 4. Therapeutic candidates 15 disease progression. Tremendous progress, however, has been made in 5. Conclusion significantly broadening the understanding of pathogenic mechanisms in 6. Expert opinion this neurological disorder that may eventually lead to successful treatment strategies. Huntington’s disease is caused by the expansion of a CAG repeat in the huntingtin gene, which results in the expression of a mutant form 20 of the protein that is toxic to neurons. Several mechanisms have been iden- tified in mediating this toxicity, such as protein aggregation, mitochondrial dysfunction, oxidative stress, transcriptional dysregulation, aberrant apop- tosis, altered proteosomal function and excitotoxicity. With increasing understanding of each of these pathogenic mechanisms, therapeutic 25 strategies have attempted to target specific aspects of each. There have been many encouraging reports of preclinical efficacy in transgenic Huntington’s disease mice, from which a number have been extended to human clinical trials with some success. This review focuses on these studies and the compounds that hold promise for treating human 30 Huntington’s disease.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Assessment Report: the Clinical Effectiveness and Cost-Effectiveness
    The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy Report commissioned by: NHS R&D HTA Programme On behalf of: The National Institute for Clinical Excellence Produced by: West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology, The University of Birmingham Authors: alphabetical Prof Stirling Bryan Senior health economist# Dr Martin Connock Systematic reviewerà Dr Carole Cummins Paediatric trials adviser† Emma Frew Health economist# Anne Fry-Smith Information specialistà Beti-Wynn Jones Systematic reviewer‡ Prof Alain Li Wan Po Pharmacological adviser†† Josie Sandercock Senior reviewerà à Department of Public Health and Epidemiology, The University of Birmingham. # Health Economics Facility, Health Services Management Centre, The University of Birmingham. † Institute of Child Health, Whittal Street, Birmingham. †† Centre for Evidence-Based Pharmacotherapy, Aston University, Birmingham. ‡ Department of Medicine Management, Keele University Correspondence to: J. Sandercock, Tel 0121-414-2247. Email [email protected] M. Connock, Tel 0121-414-7507. Email [email protected] West Midlands Health Technology Collaboration, Department of Public Health and Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT. FAX 0121- 414-7878 Date completed: February 2003 Expiry Date: Expiry date Newer Drugs for Children with Epilepsy PUBLICATION INFORMATION How to reference this publication: Connock M, Frew E, Jones B, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J. The clinical effectiveness and cost effectiveness of newer drugs for children with epilepsy. Birmingham: West Midlands Health Technology Collaboration, University of Birmingham, February 2003 ABOUT “HOME UNIT” The West Midlands Health Technology Assessment Collaboration (WMHTAC) produces rapid systematic reviews about the effectiveness of healthcare interventions and technologies, in response to requests from West Midlands Health Authorities or the HTA programme.
    [Show full text]
  • US8074644.Pdf
    USOO8074644B2 (12) United States Patent (10) Patent No.: US 8,074,644 B2 Hale et al. (45) Date of Patent: *Dec. 13, 2011 (54) METHOD OF FORMING AN AEROSOL FOR (56) References Cited NHALATION DELVERY (75) Inventors: Ron L. Hale, Sandia Park, NM (US); U.S. PATENT DOCUMENTS Craig C. Hodges, Walnut Creek, CA 1,239,634 A 9, 1917 Stuart (US); Peter M. Lloyd, Walnut Creek, CA (US); Daniel Mufson, Napa, CA (Continued) (US); Daniel D. Rogers, Oakland, CA (US); Soonho Song, Hillsborough, CA FOREIGN PATENT DOCUMENTS (US); Martin J. Wensley, Los Gatos, CA 2152684 1, 1996 CA (US); Daniel J. Myers, Mountain (Continued) View, CA (US); Jeffrey A. McKinney, Lafayette, CA (US); Reynaldo J. OTHER PUBLICATIONS Quintana, Redwood City, CA (US); U.S. Appl. No. 1 1/687,466, filed Mar. 16, 2007, Zaffaroni et al. Joshua D. Rabinowitz, Princeton, NJ (US) (Continued) (73) Assignee: Alexza Pharmaceuticals, Inc., Primary Examiner — Steven Douglas Mountain View, CA (US) (74) Attorney, Agent, or Firm — Swanson & Bratschun, (*) Notice: Subject to any disclaimer, the term of this L.L.C. patent is extended or adjusted under 35 (57) ABSTRACT U.S.C. 154(b) by 272 days. The present invention relates to the inhalation delivery of This patent is Subject to a terminal dis aerosols containing Small particles. Specifically, it relates to a claimer. method of forming an aerosol for use in inhalation therapy. In (21) Appl. No.: 12/471,070 a method aspect of the present invention, a method of forming (22) Filed: May 22, 2009 an aerosol for use in inhalation therapy is provided.
    [Show full text]